The human
tumor clonogenic assay (
HTCA) and the human
tumor xenograft system implanted in nude mice were performed simultaneously in an
ovarian cancer patient as chemosensitivity testing. Eight anticancer drugs (5-FU, MMC, VCR, ACD, BLM, VLB, CDDP, and ADM) were applied to the
HTCA and the human
tumor xenograft system. In the
HTCA,
5-FU and MMC were sensitive, VCR was moderately sensitive, and ACD, BLM, VLB, CDDP, and ADM were resistant. In the human
tumor xenograft system, MMC, VCR, and ADM showed
tumor regression (++), and CDDP, VLB, BLM,
5-FU, and ACD exhibited no response (-). Two of the three drugs, which were classified as sensitive or intermediately sensitive in the
HTCA, showed
tumor regression (++) in the human
tumor xenograft system. And four of the five drugs, which were resistant in the
HTCA, exhibited no response (-) in the human
tumor xenograft system. Clinically, PVB
therapy (CDDP, VLB, and BLM) was applied to the present patient, but after recurrence,
5-FU + MMC
therapy was applied on the basis of the results of the
HTCA. In addition, ADM was added with reference to the results of the human
tumor xenograft system. As a result of this
therapy, the
tumor growth was inhibited. It is possible from the present data that simultaneous chemosensitivity testing of the
HTCA and the human
tumor xenograft system implanted in nude mice is very useful when choosing sensitive anticancer drugs.